Duvelisib

度维利塞

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameDuvelisib
Drug Alias Name度维利司duvelisibum杜韦利西布Duvalisib度恩西布 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors
TargetsPhosphatidylinositol-4,5-Bisphosphate 3 kinase gammaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursRichter's Syndrome +[17] 
Global Approved IndicationsLymphoma, FollicularLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/24
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIntellikine LLC
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteWashington University School Of MedicineStanford University +[11] 
Inactive CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdInfinity Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center +[6] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursRichter's Syndrome +[11] 
Inactive IndicationsAsthmaHepatic InsufficiencyArthritis, Rheumatoid +[6] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG